StemCells, Inc. to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
PALO ALTO, Calif., (November 1, 2007) – StemCells, Inc. (NASDAQ: STEM) today announced that Rodney Young, Chief Financial Officer, will present a corporate update at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York, NY on Wednesday, November 7, 2007 at 1:20 p.m. Eastern Time. There will be a breakout session immediately following the presentation at which Mr. Young will be available to answer questions about the company.
A live webcast of the presentation, including the slides used in the presentation, will be available via the following link: http://www.wsw.com/webcast/rrshq12/stem or a link on the company’s web site at www.stemcellsinc.com. Replay of the presentation will be accessible for 90 days following the presentation.
About StemCells, Inc.
StemCells, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of cell-based therapeutics to treat diseases of the central nervous system, liver and pancreas. The company’s programs seek to repair or repopulate neural, liver or other tissue that has been damaged or lost as a result of disease or injury. StemCells has pioneered the discovery and development of HuCNS-SC ® cells, its highly purified, expandable population of human neural stem cells. StemCells is currently conducting a Phase I clinical trial of its proprietary HuCNS-SC product candidate as a treatment for neuronal ceroid lipofuscinosis (NCL). NCL, which is often referred to as Batten disease, is a rare and fatal neurodegenerative disease that affects infants and young children. Further information about the company is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. (“the Company”). These forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management’s current views and are based on certain assumptions that may or may not ultimately prove valid. Please refer to Item 1A of the Company’s Annual Report on Form 10-K for risks and other factors that may materially affect the Company’s business operations.
#########################
CONTACT: StemCells, Inc.
Rodney Young
Chief Financial Officer
650-475-3100, Ext. 105
irpr@stemcellsinc.com
SOURCE: StemCells, Inc.
|
